SecBot SecBot
6-K ·Filed May 7, 2026

ASND

Ascendis Pharma A/S
BULLISH
Impact 7/10
Horizonmonths Processed6mo ago SEC0001612042-26-000005
Notable filing: 6-K
Actionable Insight ▲ Bullish

The strong YORVIPATH growth and positive operating income signal a fundamental inflection point. Monitor Q2 2026 for initial YUVIWEL revenue and the PRV sale proceeds, which will further strengthen liquidity. The convertible note conversion eliminates $575M in debt, potentially improving equity quality.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$246.14
T+0 close · May 7, 2026 · via day close
Latest settled
−1.09%
T+60 · $243.45
Vs SPY
−4.93%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 7 $246.14entry
  2. T+1 · 6mo ago −3.04%α −3.87% · $238.66
  3. T+5 · 6mo ago −1.04%α −2.54% · $243.58
  4. T+20 · 5mo ago −11.92%α −15.06% · $216.79
  5. T+60 · 3mo ago −1.09%α −4.93% · $243.45

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ascendis Pharma reported Q1 2026 revenue of €246.6M (+144% YoY), driven by YORVIPATH sales tripling to €196.9M. Operating profit turned positive to €24.8M vs a loss of €104.2M, and net profit of €629.3M included a €679.0M deferred tax asset recognition. Subsequent events include FDA approval of YUVIWEL and a $187.5M PRV sale, strengthening the balance sheet.

Key Facts

  • Revenue €246.6M, up 144% YoY (Q1 2025: €100.95M)
  • Operating profit €24.8M vs loss of €104.2M YoY
  • Net profit €629.3M (includes €679.0M deferred tax asset recognition)
  • Basic EPS €10.20 vs -€1.58 YoY
  • YORVIPATH revenue €196.9M, up 341% YoY
  • Cash and cash equivalents €572.8M at March 31, 2026
  • YUVIWEL (navepegritide) FDA approval for achondroplasia in February 2026
  • Agreement to sell Rare Pediatric Disease PRV for $187.5M on May 6, 2026
  • Completed conversion of $575M convertible notes into equity on May 6, 2026

Financial Impact

Revenue increased by €145.6M YoY; operating profit improved by €129.0M; net profit includes €679.0M non-cash deferred tax benefit

revenueoperating_profitnet_incomeepscash_and_cash_equivalents

Risk Factors

  • BioMarin patent litigation (ITC trial ongoing) could impact YUVIWEL commercialization
  • Foreign exchange headwinds (USD/EUR volatility) may affect reported revenue
  • Uncertainty around tariff measures on pharmaceutical products
  • Sustained profitability depends on continued commercial execution for YORVIPATH and YUVIWEL

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
96% bullish (24 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001612042-26-000005
Document: 0001612042-26-000005-index-headers.html0001612042-26-000005
Document: 0001612042-26-000005-index.html0001612042-26-000005
Document: 0001612042-26-000005.txt0001612042-26-000005

Track record

41 reports on ASND

Performance horizon

14 of 18 bullish or bearish reports moved the stock their way by T+60. Best: +26.62% at T+20 after the Jun 2, 2026 report. 24 of 26 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $271.96 Now $271.63 −0.12% settles Feb 12
  2. Nov 12, 20263d ago 6-K Neutral 2/10 Entry $267.07 Now $271.63 +1.71% settles Feb 11
  3. Nov 12, 20264d ago 6-K Bullish 6/10 Entry $267.07 Now $271.63 +1.71% settles Feb 10
  4. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $267.07 Now $271.63 +1.71% settles Feb 10
  5. Nov 6, 20269d ago 6-K Bullish 6/10 Entry $259.85 Now $271.63 +4.53% settles Feb 5
  6. Nov 6, 202610d ago Press Release Bullish 6/10 Entry $256.82 Now $271.63 +5.77% settles Feb 4
  7. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $253.45 Now $271.63 +7.17% settles Feb 3
  8. Nov 2, 202613d ago Institutional Cluster Bullish 4/10 Entry $250.17 Now $271.63 +8.58% settles Feb 1
  9. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $245.85 Now $271.63 +10.49% settles Jan 25
  10. Oct 16, 20264w ago 6-K Bullish 7/10 Entry $225.25 Now $271.63 +20.59% settles Jan 13
Showing 10 of 41

US Market Status

Market Open · Closes in 12m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026